SSA
ESPR

Schonfeld Strategic Advisors’s Esperion Therapeutics ESPR Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4M Buy
+1,265,010
New +$3.54M 0.01% 740
2026
Q1 		– Sell
-75,238
Closed -$278K – 2349
2025
Q4 		$278K Buy
+75,238
New +$243K ﹤0.01% 1597
2024
Q4 		– Sell
-518,100
Closed -$855K – 2117
2024
Q3 		$855K Sell
518,100
-329,627
-39% -$666K 0.01% 1212
2024
Q2 		$1.88M Sell
847,727
-99,779
-11% -$235K 0.01% 935
2024
Q1 		$2.54M Sell
947,506
-143,822
-13% -$349K 0.02% 905
2023
Q4 		$3.26M Sell
1,091,328
-140,499
-11% -$182K 0.02% 641
2023
Q3 		$1.21M Sell
1,231,827
-84,273
-6% -$122K 0.01% 963
2023
Q2 		$1.83M Sell
1,316,100
-493,811
-27% -$690K 0.02% 777
2023
Q1 		$2.88M Buy
1,809,911
+1,102,859
+156% +$5.69M 0.03% 597
2022
Q4 		$4.4M Sell
707,052
-96,017
-12% -$687K 0.04% 513
2022
Q3 		$5.38M Buy
803,069
+743,069
+1,238% +$5.1M 0.05% 509
2022
Q2 		$382K Sell
60,000
-46,900
-44% -$266K ﹤0.01% 1523
2022
Q1 		$496K Sell
106,900
-183,400
-63% -$787K ﹤0.01% 1377
2021
Q4 		$1.45M Buy
290,300
+276,543
+2,010% +$2.21M 0.01% 793
2021
Q3 		$166K Sell
13,757
-46,308
-77% -$674K ﹤0.01% 1819
2021
Q2 		$1.27M Buy
+60,065
New +$1.45M 0.01% 857
2019
Q4 		– Sell
-182,019
Closed -$6.67M – 1345
2019
Q3 		$6.67M Buy
+182,019
New +$7.21M 0.2% 136
2018
Q1 		– Sell
-3,265
Closed -$215K – 823
2017
Q4 		$215K Buy
+3,265
New +$176K 0.02% 661
2016
Q4 		– Sell
-20,062
Closed -$278K – 575
2016
Q3 		$278K Buy
+20,062
New +$227K 0.05% 323

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.56% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Schonfeld Strategic Advisors's ESPR Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 1,265,010 shares worth $4M. The stake represents 0.01% of the portfolio and ranks #740 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in ESPR as recently as Q4 2025.

Schonfeld Strategic Advisors first reported a position in ESPR in Q3 2016 and has held it in 19 quarters since. The position peaked at $6.67M in Q3 2019. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Schonfeld Strategic Advisors held 1,265,010 shares of Esperion Therapeutics worth $4M as of Q2 2026.
  • Esperion Therapeutics was a new Schonfeld Strategic Advisors position in Q2 2026.
  • Esperion Therapeutics made up 0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #740 holding.
  • Schonfeld Strategic Advisors first reported a position in Esperion Therapeutics in Q3 2016 and has held it in 19 quarters since.
  • Schonfeld Strategic Advisors's Esperion Therapeutics position peaked at $6.67M in Q3 2019.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.